About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
ecancer
ecancer.org
ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.
ELCC 2024
EAU 2024
ASCO GU 2024
ASCO GI 2024
AORTIC 2023
ASH 2023
SABCS 2023
ESMO 2023
Common Sense Oncology
WCLC 2023
ESMO WCGIC 2023
ASCO® 2023
EHA® 2023
ELCC 2023
ASCO GU 2023
BGICC 2023
ASCO GI 2023
SABCS 2022
ESMO 2022
WCLC 2022
EHA 2022
ASCO 2022
ASCO 2021
Lymphoma
Leukemia
Myeloma
GYN Cancers
Head&Neck Cancers
GI Cancers
Breast Cancers
GU Cancers
Lung Cancers
Skin Cancers
Basic Science
Supportive & Palliative Care
Business
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
2020 ESMO Update on PSMA-Targeted BITE IO in mCRPC: Could AMG 160 Sit in the Treatment Landscape of mCRPC?
By
ecancer
FEATURING
Ben Tran
By
ecancer
FEATURING
Ben Tran
5 views
October 29, 2020
0 Comments
Login to view comments.
Click here to Login
Featured Video
21:09
Exelixis
Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…
Feat.
S. Ratnam
Featured Video
20:00
Exelixis
Child-Pugh Classification and its Role in Treatment Decisions in Pat…
Feat.
P. Gholam
GU Cancers
09:38
ecancer
Radiation Therapy After Radical Surgery in Prostate Cancer
Feat.
R. Paz
05:36
ecancer
EAU 2022 Update on PC Screening: A Novel Risk Prediction Tool With S…
Feat.
L. Björnebo
08:18
ecancer
Bladder Cancer: Current State and Future Directions in Treatment
Feat.
J. Garcia
04:09
ecancer
ASCO GU 2022 on the ATLANTIS Trial: Maintenance PARPi Following Chem…
Feat.
S. Crabb
06:38
ecancer
ASCO GU 2022 Updates on the Survival Benefit of Cabo + Nivo in aRCC
Feat.
C. Suárez
17:59
ecancer
ASCO GU 2022: Latest Developments in mHSPC
Feat.
K. Miller,
L. Krabbe
06:40
ecancer
ASCO GU 2022 Updates on the First Randomized Trial on Adjuvant Mitot…
Feat.
A. Berruti
28:33
ecancer
ASCO GU 2022: The Latest in CRPC + PARP Combo Data
Feat.
E. Efstathiou,
A. Merseburger,
G. Attard,
N. Clarke
25:36
ecancer
ASCO GU 2022: Latest Updates in mHSPC
Feat.
E. Efstathiou,
K. Fizazi,
K. Chi,
M. Smith
11:20
ecancer
ASCO GU 2022: PARPi in Prostate Cancer - MAGNITUDE Trial
Feat.
N. Shore,
K. Chi
09:09
ecancer
ESMO 2021 Highlights on Nivo With Alternatively Scheduled Ipi in 1L …
Feat.
N. Vasudev
21:15
ecancer
PARPi in Prostate Cancer: Case Based Testing and Clinical Decisions
Feat.
N. Shore,
F. Saad
33:50
ecancer
Advances in Prostate Cancer in the Last 10 Years and a Glimpse to th…
Feat.
L. Krabbe,
K. Fizazi,
J. de Bono
06:06
ecancer
ESMO 2021 Update on Enzalutamide + ADT in Men With mHSPC: Final OS A…
Feat.
A. Armstrong
32:06
ecancer
QoL and Safety in Novel Therapies for Prostate Cancer
Feat.
H. Payne,
A. Morgans,
B. Tombal
26:35
ecancer
ESMO 2021 Updates in HSPC: OS Analysis From ARCHES, STAMPEDE, and PE…
Feat.
E. Efstathiou,
A. Merseburger,
N. Mottet,
E. Castro
35:58
ecancer
ESMO 2021: PARPi Data and Their Role in Mono/Combination Therapies
Feat.
N. Shore,
E. Efstathiou,
F. Saad,
A. Armstrong
38:47
ecancer
ESMO 2020 Update on Advanced PC: What Is the Efficacy of PARP Inhibi…
Feat.
N. Shore,
E. Castro,
N. Agarwal,
K. Chi
05:25
ecancer
2020 ESMO Updates on Stage 4 GU Cancers: Olaparib in CRPC, Ipatasert…
Feat.
B. Gyawali
12:06
ecancer
ESMO Updates on FGFR-2&3-Mutated Bladder Cancer: Is Selecting Pa…
Feat.
Y. Loriot,
S. Tagawa
05:12
ecancer
ESMO Updates on Advanced RCC: Will Nivo+Cabozantinib Become a New So…
Feat.
T. Choueiri
05:19
ecancer
ESMO Updates on Advanced PC: What Are the Key Survival Outcomes With…
Feat.
J. Mateo
05:27
ecancer
ASCO IMvigor130 Updates on mUC: Does Atezo+/-Chemo Improve PFS/OS?
Feat.
M. Galsky
14:21
ecancer
2020 ESMO Update on nmCRPC: What Are the MFS Benefits With Apalutami…
Feat.
H. Payne,
S. Oudard
13:18
ecancer
2020 Updates on Genetic Testing in PC: Who Should Be Tested for DDR …
Feat.
N. Shore,
E. Castro
13:45
ecancer
2020 ASCO Updates on Bladder Cancer: Should We Give IO in the Mainte…
Feat.
A. Siefker-Radtke,
Y. Loriot
09:48
ecancer
2020 ASCO Update on PARPi in mCRPC: Is BRCA1/2 Correlated With the B…
Feat.
E. Antonarakis
09:04
ecancer
2020 ESMO Updates from the STAMPEDE Trial on ADT in mHSPC: Are We Re…
Feat.
E. Efstathiou,
B. Hadaschik,
J. de Bono,
N. James
08:58
ecancer
ESMO 2020 Update on nmCRPC: Should We Use Chemotherapy in Hormone-Na…
Feat.
E. Efstathiou,
B. Hadaschik,
J. de Bono,
N. James
21:42
ecancer
2020 ESMO Updates in mCRPC: What Does the PROfound Trial Suggest for…
Feat.
E. Efstathiou,
B. Hadaschik,
J. de Bono,
N. James
05:27
ecancer
2020 ESMO Update on PSMA-Targeted BITE IO in mCRPC: Could AMG 160 Si…
Feat.
B. Tran
